MARKET OUTLOOK
Triton Market Research has estimated the Europe hyperphosphatemia drugs market to show an upward trend in terms of revenue and grow rapidly with a CAGR of 16.11% in the forecasting years 2019-2027.
France, Italy, the United Kingdom, Germany, Russia, Spain and countries in rest of Europe together form the market for hyperphosphatemia drugs in the European region.
The growing aging population and increasing osteoporosis cases in the UK are the major driving factors strengthening the demand for the hyperphosphatemia drugs market in the country. In the UK, around 3 million people are expected to be suffering from osteoporosis. Additionally, more than 230,000 fracture cases are recorded every year due to osteoporosis. A low level of estrogen in women or other hormone might significantly increase the risk of weakening the bones.
The increasing aging population in Spain is considered as the major driving factor to strengthen the demand of the hyperphosphatemia drugs market in the country. Spain accounts for a significant proportion of elderly population within Europe. By 2050, one-fourth of Spain’s population is estimated to be over 100 years. The aging population can be considered as the most crucial reason for the rising prevalence of hyperphosphatemia disorders that is driving the growth of the Spain market. In cases of chronic kidney diseases and elderly people, the loss of phosphorus homeostasis due to phosphorus excretion failure causes hyperphosphatemia. And this is growing the demand for the hyperphosphatemia drugs market in the country.
COMPETITIVE OUTLOOK
The companies contending in the market are Fermenta Biotech, Ltd., Sanofi, Roche Diagnostics Corporation, Pfizer, Inc., Royal DSM N.V., Fresenius Medical Care, Sun Pharmaceutical Industries, Ltd., Cipla, AMAG Pharmaceuticals, Keryx Biopharmaceuticals, Inc., Bio-Tech Pharmacal, Ultragenyx Pharmaceutical, Inc., Johnson and Johnson, Shire, Zeria Pharmaceutical and Bruno Farmaceutici S.p.A.